Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniel W. Hugenberg"'
Publikováno v:
Clinical Pharmacology: Advances and Applications. 12:35-41
Background High on-treatment ADP platelet reactivity (HPR) measured by VerifyNow P2Y12 assay (VN) is an established risk factor for ischemic events after percutaneous coronary intervention (PCI). We hypothesized that routine use of VN at time of PCI
Publikováno v:
Journal of Thrombosis and Thrombolysis. 50:619-627
High on treatment platelet reactivity (HPR) during treatment with clopidogrel has been consistently found to be strong risk factor for recurrent ischemic events after percutaneous coronary intervention (PCI). Insufficient P2Y12 receptor inhibition co
Publikováno v:
Clinical Pharmacology : Advances and Applications
Background High on-treatment ADP platelet reactivity (HPR) measured by VerifyNow P2Y12 assay (VN) is an established risk factor for ischemic events after percutaneous coronary intervention (PCI). We hypothesized that routine use of VN at time of PCI
Publikováno v:
Journal of Cardiac Failure. 22:S95
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 35-41 (2020)
Fakilahyel S Mshelbwala, Daniel W Hugenberg, Rolf P Kreutz Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence: Rolf P KreutzKrannert Institute of Cardiology, Department of Medicine, Indiana Un
Externí odkaz:
https://doaj.org/article/27a02000a6014ec2bc26522c37139402
Publikováno v:
Journal of Thrombosis & Thrombolysis; Oct2020, Vol. 50 Issue 3, p619-627, 9p